{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Condado-Morales I"],"funding":["Novo Nordisk STAR Fellowship"],"pubmed_abstract":["Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by developability challenges. Here, we systematically analyzed 64 different antibody constructs targeting Tumor Necrosis Factor (TNF) which cover 8 distinct molecular format families, encompassing full-length antibodies, various types of single chain variable fragments, and bispecifics. We measured 15 biophysical properties related to activity, manufacturing, and stability, scoring variants with a flag-based risk approach and a recent <i>in silico</i> developability profiler. Our comparative asses"],"journal":["mAbs"],"pagination":["2403156"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11457596"],"repository":["biostudies-literature"],"pubmed_title":["A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs."],"pmcid":["PMC11457596"],"pubmed_authors":["Hummer AM","Patel B","Rose Bjelke J","Bennet A","Lorenzen N","Arosio P","Raybould MIJ","Turnbull OM","Condado-Morales I","Egebjerg T","Deane CM","Dingfelder F","Cao Z","Waibel I","Nedergaard Grell S"],"additional_accession":[]},"is_claimable":false,"name":"A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs.","description":"Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by developability challenges. Here, we systematically analyzed 64 different antibody constructs targeting Tumor Necrosis Factor (TNF) which cover 8 distinct molecular format families, encompassing full-length antibodies, various types of single chain variable fragments, and bispecifics. We measured 15 biophysical properties related to activity, manufacturing, and stability, scoring variants with a flag-based risk approach and a recent <i>in silico</i> developability profiler. Our comparative asses","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan-Dec","modification":"2025-04-26T20:13:21.725Z","creation":"2025-04-06T16:23:34.693Z"},"accession":"S-EPMC11457596","cross_references":{"pubmed":["39364796"],"doi":["10.1080/19420862.2024.2403156"]}}